Sanofi launches dengue immunisation program in Brazil
August 15, 2016Research and Development, Sales and Marketing Brazil, Sanofi, Sanofi Pasteur, Vaccine, dengue, immunisation, vaccines
Sanofi has announced that it has initiated the first dengue immunisation public program in the Americas, with 500,000 individuals set …
Study shows promise for Venclexta in acute myelogenous leukaemia
August 12, 2016Research and Development, Sales and Marketing AbbVie, Genentech, Roche, Venclexta, venetoclax
A study published in Cancer Discovery, the journal of the American Association for Cancer Research, suggests that Vencletxa (venetoclax) is …
Promising results for new type 2 diabetes management procedure
August 12, 2016Research and Development, Sales and Marketing Fractyl, Revita, diabetes, type 2 diabetes
Fractyl Laboratories has revealed data from its first-in-human study of Revita duodenal mucosal resurfacing (Revita DMR), a new 60-minute, non-surgical …
Ashfield publishes a guide to Patient Support Programmes: Ten steps to success
August 12, 2016Medical Communications, Research and Development, Sales and Marketing
The priorities of Pharma and healthcare organisations are better aligned as a result of the industry’s increased efforts to put …
Number of babies born with opioid dependence has tripled in US, says CDC report
August 12, 2016Medical Communications, Research and Development CDC, addicted, babies, opioid dependence, opioids
A new report from the Centers for Disease Control and Prevention (CDC) has highlighted a sharp increase in the number …
Allergan set to acquire eye-care biotech ForSight VISION5
August 12, 2016Medical Communications, Sales and Marketing Allergan, ForSight VISION5, acquisition, biotech, eye care
Allergan has announced its acquisition of privately-held, clinical-stage eye-care biotech ForSight VISION5 for a $95 million upfront payment and a …
Novartis admits employees gave kickbacks to doctors in South Korea
August 12, 2016Medical Communications, Research and Development Novartis, kickbacks, south korea
Novartis has confirmed that six employees in South Korea gave kickbacks to doctors, as the current and former employees face …
Advaxis follows up Amgen deal with Phase IIa cancer trial success
August 12, 2016Medical Communications, Research and Development Advaxis, immunotherapy. cancer. Amgen
Advaxis, a US biotech in cancer immunotherapy development, has announced that its lead immunotherapy product axalimogene filolisbac (AXAL) has hit …
Gilead to work with Genmab on HIV targeting technology
August 12, 2016Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …
Thousands to benefit with new anti-clotting drug recommendation, says NICE
August 12, 2016Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor
The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …
Valeant under criminal investigation
August 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, investigation
Valeant Pharmaceuticals International is currently under investigation by the US attorney’s office in Manhattan over suspicions that the firm intentionally …
FDA accepts Marathon’s Duchenne drug for priority review
August 11, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …
Heron Therapeutics gets FDA approval for chemotherapy-induced nausea drug
August 11, 2016Research and Development, Sales and Marketing FDA, chemotherapy-induced nausea, granisetron, heron therapeutics, sustol
Heron Therapeutics has announced that it has received US Food and Drug Administration (FDA) approval for Sustol (granisetron) for the …
Chronos Therapetics strengthens management with two new vice presidents
August 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Private biotech Chronos Therapeutics has announced two new additions to its management team; Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl …
New senior VP, finance at Eli Lilly
August 10, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly
Eli Lilly has announced that Joshua Smiley is set to become senior vice president, finance, and treasurer from October 1, …
New Agilent expansion will ‘more than double’ nucleic acid API manufacture
August 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Agilent, expansion, manufacturing, oligonucleotide
Agilent Technologies is set to expand its pharmaceutical manufacturing operations with a 20-acre facility in Weld County, Colorado. The facility …
Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer
August 10, 2016Research and Development Eli Lilly, abemaciclib, breast cancer
Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …
Valeant stock rises despite weak Q2 results
August 10, 2016Research and Development, Sales and Marketing Valeant, financial results
Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
Biogen names haemophilia spin-off Bioverativ
August 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ
Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …
Experimental stem cell treatment shows promise in rheumatoid arthritis
August 10, 2016Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment
Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
